Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/06/26
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law FirmBusiness Wire • 03/20/26
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCABusiness Wire • 03/20/26
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCABusiness Wire • 03/19/26
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewsWire • 03/11/26
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026GlobeNewsWire • 03/05/26
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewsWire • 02/23/26
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii PharmaceuticalGlobeNewsWire • 02/09/26
Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's WhyZacks Investment Research • 02/02/26
How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11%Zacks Investment Research • 01/12/26
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common WartsGlobeNewsWire • 01/07/26
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash RunwayGlobeNewsWire • 11/24/25
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual MeetingGlobeNewsWire • 11/10/25
Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their RightsBusiness Wire • 10/24/25
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European UnionGlobeNewsWire • 10/20/25
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 10/07/25
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum ContagiosumGlobeNewsWire • 09/19/25
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 09/02/25
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat EstimatesZacks Investment Research • 08/12/25